» Articles » PMID: 39857445

Molecular Hydrogen Modulates T Cell Differentiation and Enhances Neuro-Regeneration in a Vascular Dementia Mouse Model

Overview
Date 2025 Jan 25
PMID 39857445
Authors
Affiliations
Soon will be listed here.
Abstract

This study explores whether molecular hydrogen (H) administration can alleviate cognitive and immunological disturbances in a mouse model of vascular dementia (VaD). Adult male C57BL/6 mice underwent bilateral common carotid artery stenosis to induce VaD and were subsequently assigned to three groups: VaD, VaD with hydrogen-rich water treatment (VaD + H), and Sham controls. Behavioral assessments using open field and novel object recognition tests revealed that VaD mice exhibited anxiety-deficient behavior and memory impairment, both of which were reversed by H treatment. Histological examinations showed pyknotic neuronal morphologies and elevated reactive oxygen species (ROS) in the VaD hippocampus, whereas H administration mitigated these alterations. Furthermore, VaD-induced downregulation of BCL2 was reversed in the VaD + H group, in parallel with increased IL-4 expression. Flow cytometric analyses revealed that VaD disrupted T regulatory cell homeostasis by significantly increasing their proportion, an effect reversed by H treatment, thereby restoring immunological balance. Transcriptomic evaluations confirmed that VaD suppressed key neuroprotective and anti-inflammatory genes, while H treatment restored or enhanced their expression. Collectively, these findings highlight the neuroprotective and immuno-modulatory potential of molecular hydrogen, suggesting that H supplementation may promote neuronal resilience, modulate T cell differentiation, and support cognitive recovery in vascular dementia.

References
1.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H . Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348(14):1333-41. DOI: 10.1056/NEJMoa013128. View

2.
Jellinger K . Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci. 2013; 5:17. PMC: 3622231. DOI: 10.3389/fnagi.2013.00017. View

3.
Knopman D, Rocca W, Cha R, Edland S, Kokmen E . Survival study of vascular dementia in Rochester, Minnesota. Arch Neurol. 2003; 60(1):85-90. DOI: 10.1001/archneur.60.1.85. View

4.
Fitzpatrick A, Kuller L, Lopez O, Kawas C, Jagust W . Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci. 2005; 229-230:43-9. DOI: 10.1016/j.jns.2004.11.022. View

5.
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K . Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019; 5:272-293. PMC: 6617248. DOI: 10.1016/j.trci.2019.05.008. View